Wave Life Sciences Ltd (WVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has a cash flow conversion efficiency ratio of -0.061x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.12 Million) by net assets ($526.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wave Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read WVE current and long-term liabilities for a breakdown of total debt and financial obligations.
Wave Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wave Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hoist Finance AB
ST:HOFI
|
0.067x |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
-0.056x |
|
Danya Cebus
TA:DNYA
|
0.057x |
|
Derichebourg
PA:DBG
|
0.205x |
|
Wuxi Longsheng Technology Co Ltd
SHE:300680
|
0.058x |
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
0.165x |
|
Willis Lease Finance Corporation
NASDAQ:WLFC
|
0.090x |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
0.030x |
Annual Cash Flow Conversion Efficiency for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Wave Life Sciences Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.23 Million | $-187.49 Million | -0.356x | +50.57% |
| 2024-12-31 | $209.51 Million | $-151.03 Million | -0.721x | -47.02% |
| 2023-12-31 | $39.63 Million | $-19.43 Million | -0.490x | -117.30% |
| 2022-12-31 | $-45.09 Million | $-127.78 Million | 2.834x | +203.48% |
| 2021-12-31 | $32.50 Million | $-88.99 Million | -2.738x | -114.04% |
| 2020-12-31 | $90.65 Million | $-115.98 Million | -1.279x | +51.33% |
| 2019-12-31 | $71.61 Million | $-188.23 Million | -2.629x | -743.37% |
| 2018-12-31 | $73.35 Million | $-22.86 Million | -0.312x | +47.92% |
| 2017-12-31 | $139.81 Million | $-83.67 Million | -0.598x | -153.23% |
| 2016-12-31 | $134.86 Million | $-31.87 Million | -0.236x | -189.57% |
| 2015-12-31 | $153.49 Million | $-12.53 Million | -0.082x | +96.26% |
| 2014-12-31 | $2.03 Million | $-4.43 Million | -2.184x | -577.29% |
| 2013-12-31 | $-7.76 Million | $-3.55 Million | 0.457x | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more